FDA User Fees To Speed Drug Review

Despite some concerns over the potential for harm to innovation at small firms and undue influence and increased bureaucracy at the agency, government and industry analysts are expressing enthusiasm for a statute requiring pharmaceutical companies to pay "user fees" to the United States Food and Drug Administration. The additional 600 reviewers the fees will finance, they say, will result in decreased review time that will reduce corporate cost, increase government efficiency, and, ultimately,

| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

There is even the possibility--though no drug maker will commit to it--that savings will be passed on to the consumer in terms of lower prices on pharmacy shelves.

The new legislation, aimed at clearing the logjam of drugs waiting for approval at FDA, requires pharmaceutical firms to pay $330 million in user fees directly to the agency over the next five years.

With the additional reviewers these fees will provide, the agency has pledged to cut the time it takes to review new products in half by October 1997.

Testifying on the bill before the Senate Committee on Labor and Human Resources, Irwin Lerner, president and CEO of Hoffmann-La Roche, Inc., Nutley, N.J., commented: "It has been refreshing to see how well the private and public sector can work together for the public good."

But other observers, including some physicians and legislators, are uncomfortable with the close ties the bill ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • Susan L-J Dickinson

    This person does not yet have a bio.

Published In

Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide

Explore a Concise Guide to Optimizing Viral Transduction

A Visual Guide to Lentiviral Gene Delivery

Takara Bio
Inventia Life Science

Inventia Life Science Launches RASTRUM™ Allegro to Revolutionize High-Throughput 3D Cell Culture for Drug Discovery and Disease Research

An illustration of differently shaped viruses.

Detecting Novel Viruses Using a Comprehensive Enrichment Panel

Twist Bio